CAC 40
8 049,19 -15,96 (-0,20 %) Euro Stoxx 50
4 962,85 -18,24 (-0,37 %) Dow Jones
38 386,09 +146,43 (+0,38 %) EUR/USD
1,0707 -0,0018 (-0,17 %) Gold future
2 324,30 -33,40 (-1,42 %) Bitcoin EUR
58 726,11 -631,68 (-1,06 %)
Knight Therapeutics Inc. (GUD.TO)
Knight Therapeutics Inc.
3400 de Maisonneuve Boulevard West
Suite 1055
Montreal, QC H3Z 3B8
Canada
514-484-4483
https://www.gud-knight.com
Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - Specialty & Generic
Employés à temps plein: 725
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Mr. Jonathan Ross Goodman B.A., L.L.B., M.B.A. | Executive Chairman | 250,94k | S.O. | 1969 |
| Ms. Samira Sakhia BCom, CA, CPA, MBA | President, CEO & Director | 674,28k | S.O. | 1968 |
| Mr. Arvind Utchanah | Chief Financial Officer | 607,22k | S.O. | S.O. |
| Ms. Amal Khouri B.Sc., M.B.A. | Chief Business Officer | 519,87k | S.O. | S.O. |
| Mr. Jeff Martens | Global Vice President of Commercial | 420,4k | S.O. | S.O. |
| Mr. Stephani Saverio | Vice President of Business Development | 440,65k | S.O. | S.O. |
| Mr. Leopoldo Bosano | Vice-President of Manufacturing & Operations | S.O. | S.O. | S.O. |
| Ms. Monica Percario | Global Vice President of Scientific Affairs | S.O. | S.O. | S.O. |
| Mr. Henrique Dias | Global Director of Marketing | S.O. | S.O. | S.O. |
| Ms. Susan Caroline Emblem | Global Vice President of Human Resources | S.O. | S.O. | S.O. |
Description
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Knight Therapeutics Inc. en date du 1 avril 2024 est 5. Les scores principaux sont Audit : 7; Société : 5; Droits des actionnaires : 7; Compensation : 5.
